NexgenRx Inc

NexgenRx maintains a conservative capital structure with a debt-to-equity ratio of 0.05, indicating minimal leverage and a strong equity base. The company's liquidity position is characterized as medium, with a current ratio of 1.13, suggesting it can cover its short-term obligations but with limited buffer. Free cash flow of CAD 638,010 supports operational flexibility, though capital expenditures were negative at CAD -345,030, indicating asset disposals or reduced investment. Profitability metrics show a return on equity of 16.92%, which is strong relative to the industry's typical performance, while return on assets of 3.52% suggests moderate efficiency in asset utilization. The company's operating income of CAD 1,935,570 and net income of CAD 1,289,740 reflect a healthy margin structure, with gross profit of CAD 14,933,910 supporting its service-based business model. Geographically, NexgenRx's revenue is concentrated in Canada, with no disclosed international operations. The company's business is primarily driven by domestic health benefit plan administration, with no material diversification across regions or segments. Growth trajectory is supported by a revenue base of CAD 17,932,420, with no disclosed YoY growth rate. The company's outlook for the current fiscal year is stable, with no significant changes in revenue or operating performance expected in the near term. Risk factors include a medium liquidity risk due to a current ratio near 1.0 and a negative net cash position after subtracting total debt. Dilution risk is low, with no near-term pressure from share issuance or convertible instruments. Recent events include no material filings or transcripts disclosed in the input data. The company's operations remain focused on its core third-party administration and technology solutions for healthcare claims.